Thiopurine-methyltransferase and inosine triphosphate pyrophosphatase polymorphism in a liver transplant recipient developing nodular regenerative hyperplasia on low-dose azathioprine

European Journal of Gastroenterology and Hepatology

Volumn 20, Issue 1, 2008, Pages 68-72

  Buster, Erik H C J ^a   Van Vuuren, Hanneke J ^a   Zondervan, Pieter E ^a   Metselaar, Herold J ^a   Tilanus, Hugo W ^a   De Man, Robert A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Azathioprine; Inosine triphosphate pyrophosphatase; Liver transplantation; Nodular regenerative hyperplasia; Thiopurinemethyltransferase

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CYCLOSPORIN A; GAMMA GLUTAMYLTRANSFERASE; INOSINE TRIPHOSPHATE PYROPHOSPHATASE; ISOENZYME; LIVER ENZYME; PREDNISONE; THIOPURINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLEEDING; CASE REPORT; DRUG WITHDRAWAL; ENZYME POLYMORPHISM; FEMALE; GENOTYPE; GRAFT RECIPIENT; HEPATIC ENCEPHALOPATHY; HEPATITIS B; HETEROZYGOSITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FAILURE; LIVER BIOPSY; LIVER GRAFT REJECTION; LIVER HYPERPLASIA; LIVER TRANSPLANTATION; LOW DRUG DOSE; LYMPHOCYTE; NODULAR REGENERATIVE HYPERPLASIA; PORTAL HYPERTENSION; PRIORITY JOURNAL; SIDE EFFECT;

ADULT; AZATHIOPRINE; ESOPHAGEAL AND GASTRIC VARICES; FEMALE; HEPATITIS B; HETEROZYGOTE; HUMANS; HYPERPLASIA; IMMUNOSUPPRESSIVE AGENTS; LIVER; LIVER TRANSPLANTATION; LYMPHOCYTES; METHYLTRANSFERASES; POLYMORPHISM, GENETIC; POSTOPERATIVE COMPLICATIONS; PYROPHOSPHATASES; THROMBOSIS; TREATMENT OUTCOME;

EID: 37349020952     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32825a6a8a     Document Type: Article

References (15)

1. Al Hadithy AF, de Boer NK, Derijks LJ, Escher JC, Mulder CJ, Brouwers JR. Thiopurines in inflammatory bowel disease: pharmacogenetics, therapeutic drug monitoring and clinical recommendations. Dig Liver Dis 2005; 37:282-297.
2. Mion F, Napoleon B, Berger F, Chevallier M, Bonvoisin S, Descos L. Azathioprine induced liver disease: nodular regenerative hyperplasia of the liver and perivenous fibrosis in a patient treated for multiple sclerosis. Gut 1991; 32:715-717.
3. Marinaki AM, Ansari A, Duley JA, Arenas M, Sumi S, Lewis CM, et al. Adverse drug reactions to azathioprine therapy are associated with polymorphism in the gene encoding inosine triphosphate pyrophosphatase (ITPase). Pharmacogenetics 2004; 14:181-187.
4. Dubinsky MC, Lamothe S, Yang HY, Targan SR, Sinnett D, Theoret Y, et al. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease. Gastroenterology 2000; 118:705-713.
5. Breen DP, Marinaki AM, Arenas M, Hayes PC. Pharmacogenetic association with adverse drug reactions to azathioprine immunosuppressive therapy following liver transplantation. Liver Transpl 2005; 11:826-833.
6. Sumi S, Marinaki AM, Arenas M, Fairbanks L, Shobowale-Bakre M, Rees DC, et al. Genetic basis of inosine triphosphate pyrophosphohydrolase deficiency. Hum Genet 2002; 111:360-367.
7. Gearry RB, Roberts RL, Barclay ML, Kennedy MA. Lack of association between the ITPA 94C > A polymorphism and adverse effects from azathioprine. Pharmacogenetics 2004; 14:779-781.
8. van Dieren JM, van Vuuren AJ, Kusters JG, Nieuwenhuis EE, Kuipers EJ, van der Woude CJ. ITPA genotyping is not predictive for the development of side effects in AZA treated inflammatory bowel disease patients. Gut 2005; 54:1664.
9. Gane E, Portmann B, Saxena R, Wong P, Ramage J, Williams R. Nodular regenerative hyperplasia of the liver graft after liver transplantation. Hepatology 1994; 20(1 Pt 1):88-94.
10. Wanless IR. Micronodular transformation (nodular regenerative hyperplasia) of the liver: a report of 64 cases among 2500 autopsies and a new classification of benign hepatocellular nodules. Hepatology 1990; 11:787-797.
11. de Boer NK, Derijks LJ, Gilissen LP, Hommes DW, Engels LG, de-Boer SY, et al. On tolerability and safety of a maintenance treatment with 6-thioguanine in azathioprine or 6-mercaptopurine intolerant IBD patients. World J Gastroenterol 2005; 11:5540-5544.
12. Okada Y, Nakamura K, Wada M, Nakamura T, Tsukamoto N, Nojima Y, et al. Genotyping of thiopurine methyltransferase using pyrosequencing. Biol Pharm Bull 2005; 28:677-6781.
13. Daniel F, Cadranel JF, Seksik P, Cazier A, Duong Van Huyen JP, Ziol M, et al. Azathioprine induced nodular regenerative hyperplasia in IBD patients. Gastroenterol Clin Biol 2005; 29:600-603.
14. De Boer NK, Mulder CJ, van Bodegraven AA. Myelotoxicity and hepatotoxicity during azathioprine therapy. Neth J Med 2005; 63:444-446.
15. Dubinsky MC, Vasiliauskas EA, Singh H, Abreu MT, Papadakis KA, Tran T, et al. 6-Thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003; 125:298-303.